- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00147264
Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial
December 13, 2016 updated by: McMaster University
A Randomized, Double Blind, 2X2 Factorial Design Study to Evaluate the Effects of Telmisartan vs Placebo, and of a Low-Glycemic Diet vs Control Diet, in Reducing Intra-Myocellular Lipids In Individuals With Abdominal Obesity
The purpose of this study is to determine whether telmisartan and/or a low-glycemic index diet are effective in reducing intra-myocellular lipid (muscle fat) content.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The metabolic syndrome currently affects over 20% of the adult population in Canada.
Patients with abdominal obesity are at markedly increased risk for diabetes and heart disease.
Recent studies have shown that decreased sensitivity to insulin (insulin resistance), a hallmark of the metabolic syndrome, is related to increased storage of fat in muscle cells (muscle fat).
Several recent studies indicate that blocking the renin-angiotensin system (RAS) may improve insulin sensitivity and prevent the development of type 2 diabetes.
Other data suggests that this effect may be due to the effect of RAS blockade on the recruitment and growth of adipose tissue.
The primary aim of this study is therefore to explore the role of angiotensin II in the development of insulin resistance.
Specifically, we will examine the mechanisms underlying the putative anti-diabetic effect of RAS blockade by examining the effect of angiotensin receptor blockade on muscle fat content in individuals with the abdominal obesity.
This study will therefore test the hypothesis that treatment with the angiotensin receptor blocker telmisartan (Micardis®) will reduce muscle fat, thereby improving insulin sensitivity in people with abdominal obesity, with or without additional features of the metabolic syndrome.
A number of dietary factors can also affect insulin sensitivity and may influence muscle fat.
Recent studies suggest that increasing the content of low-glycemic foods (carbohydrates which are less easily digested), can improve insulin sensitivity and lipid profile in patients with insulin resistance.
A second aim of this study is therefore to test the hypothesis that a low-glycemic diet will reduce muscle fat, thereby improving insulin sensitivity in this population.
Study Type
Interventional
Enrollment
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - Cardiovascular Obesity Research and Management Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent
- Between 30 and 70 years of age
- Abdominal obesity defined as increased waist circumference (Men >102cm (>40in), Women >88cm (>35in)), with or without any of the following additional criteria of the metabolic syndrome:
- Triglycerides >=1.7mmol/L (>=150 mg/dL and/or on prescribed lipid lowering medication for > 3 months)
- HDL cholesterol
- Men <1.0 mmol/L (<40 mg/dL)
- Women <1.3 mmol/L (<50 mg/dL)
- Blood pressure >=130 and/or >=85 mmHg and/or on anti-hypertensive therapy (except ACE-I or ARB)
- Fasting glucose >=6.1 mmol/L (>=110 mg/dL)
- Ability and willingness to complete dietary and activity diaries and questionnaires.
Exclusion Criteria:
- Participant has taken ACE inhibitor or ARB in the last 3 months, or in the opinion of the study physician currently has indication for either of these medications
- Concurrent antidiabetic medication
- Use of systemic glucocorticosteroids (topical and inhaled are acceptable)
- On lipid-lowering medication and NOT on stable dose for the last three months
If the participant has any one or more of the following medical disorders:
- diabetes mellitus and/or FBG >=7.0 mmol/L on two separate occasions within the screening period
- uncontrolled hypertension (SBP >=160 mmHg and/or DBP >=100 mmHg) or known participants with secondary causes of hypertension
- biliary obstruction
- hepatic dysfunction as defined by SGPT (ALT) > 3 times the upper limit of normal range
- renal dysfunction as defined by serum creatinine > 130umol/L AND/OR proteinuria 1+ or greater (dipstick)
- serum triglycerides >10 mmol/L
- history of hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
- sodium depletion or hyperkalemia.
- uncorrected volume depletion
- endocrine disorder (e.g. hyperthyroidism, Cushing's syndrome, acromegaly, etc.) Participants on thyroid-replacement therapy and TSH < 5.0 mU/L may be enrolled in the study.
- contraindications to study diet
- any major surgery that is, at the time of screening, planned to take place during the study period.
- previously angioedema with ACE Inhibitor or ARB or known hypersensitivity to any component of the study drug formulations (e.g. hereditary fructose intolerance)
- history of drug or alcohol dependency within six months prior to signing the informed consent form.
- history of active malignancy, chronic inflammatory disorder, or chronic infections which would interfere with protocol completion.
- any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol and/or safe administration of trial medication
- If the participant has any contraindications to MRI
Pre-menopausal women (last menstruation >=1 year prior to consent) who:
- are not surgically sterile or
- are nursing, or pregnant, or
- are of child-bearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the study, AND do not agree to periodic pregnancy testing during participation in the study.
- Intention to go on weight - reducing medications or weight-loss diets during the study period
- Significant fluctuations in weight over past 3 months(e.g. >10%)
- Household member currently in study
- Any investigational drug therapy within one month of signing the informed consent form.
- Participant has knowledge that he/she will be unable to consume study foods for >2 weeks during treatment phase of study
- <70% compliant during run-in
- Unable to reduce total fat consumption to <40% and/or reduce saturated fat consumption to <15% during run-in
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
(for both interventions): change in IMCL content in the soleus muscle as assessed by 1H-MRI Spectroscopy at baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
---|
Change in intra-hepatocellular lipid storage as assessed by 1H-MRI Spectroscopy
|
Change in insulin sensitivity as determined by HOMA index
|
Reversal of IFG to normal fasting glucose in participants with IFG
|
Change in 72-hour subcutaneous glucose profile
|
Change in fasting lipid profile (free fatty acids, triglyceride, total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol)
|
Change in serum/plasma levels of inflammatory markers (C-reactive protein, adiponectin, tumor necrosis factor a, interleukin 6, leptin, adhesion molecules, plasminogen-activation inhibitor-1, t-PA, global test of fibrinolysis, fibrinogen, homocysteine,
|
Change in beta-cell function as assessed by the Insulin Secretion Index
|
Other efficacy parameters of the AT1 blockade and LGI diet are:
|
Change in waist circumference
|
Change in body composition as assessed by bioelectrical impedance analysis
|
Change in abdominal (visceral) adipose tissue as assessed by MRI
|
Change in resting blood pressure
|
Change in adipocytic cell size determined by grouped diameter distribution in subcutaneous abdominal adipose tissue biopsies
|
Changes in mRNA expression of genes in adipose tissue for genes involved in adipose tissue differentiation, growth, metabolism, cardiovascular function and inflammation.
|
Change in muscle triglyceride content (histochemical examination of muscle biopsies)
|
Change in molecular markers of endoplasmic reticular stress in circulating blood cells
|
Endothelial function as assessed by Doppler ultrasound of the forearm blood flow.
|
Systolic and diastolic cardiac function as assessed by echocardiography
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Arya M Sharma, MD, FRCPC, McMaster University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chetty VT, Damjanovic S, Gerstein H, Singh N, Yusuf S, Anand SS, Sharma AM. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press. 2014 Feb;23(1):54-60. doi: 10.3109/08037051.2013.791411. Epub 2013 Jun 3.
- Kochan AM, Wolever TM, Chetty VT, Anand SS, Gerstein HC, Sharma AM. Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. J Nutr. 2012 Jan;142(1):27-32. doi: 10.3945/jn.111.146571. Epub 2011 Nov 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Primary Completion (Actual)
January 1, 2006
Study Completion (Actual)
November 1, 2006
Study Registration Dates
First Submitted
September 2, 2005
First Submitted That Met QC Criteria
September 2, 2005
First Posted (Estimate)
September 7, 2005
Study Record Updates
Last Update Posted (Estimate)
December 14, 2016
Last Update Submitted That Met QC Criteria
December 13, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 502.433
- BI Pharmaceuticals - 502.433
- CIHR - 116099
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome X
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Federal University of São PauloCompletedPhysical Activity | Endothelial Dysfunction | Metabolic Syndrome xBrazil
-
Midwest Biomedical Research FoundationSuspended
-
Instituto de Seguridad y Servicios Sociales de...Enrolling by invitationCardiovascular Diseases | Mediterranean Diet | Metabolic Syndrome xMexico
-
Wake Forest University Health SciencesBrigham and Women's HospitalCompletedDiabetes | Metabolic Syndrome xUnited States
-
University of PennsylvaniaAbbottCompletedMetabolic Syndrome xUnited States
-
Queen Margaret UniversityUnknownCardiovascular Diseases | Metabolic Syndrome XUnited Kingdom
-
Arne AstrupUniversity of Aarhus; University Hospital, Gentofte, Copenhagen; Technical University...CompletedMetabolic Syndrome XDenmark
Clinical Trials on Telmisartan (Micardis®) vs. Placebo
-
Boehringer IngelheimCompleted
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Coordinación de Investigación en Salud, MexicoCompletedInflammation | End-stage Renal DiseaseMexico
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedObesity | Insulin ResistanceItaly, United States, Canada, Germany, Denmark
-
Boehringer IngelheimCompleted
-
University of HawaiiQueens Medical CenterTerminated
-
Boehringer IngelheimCompleted